ArticleDiscover oncology2025
High expression of GRB14 is associated with cancer progression and poor prognosis in gastric cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGrowth factor receptor-bound protein 14 (GRB14) has emerged as a significant regulator in cancer progression and prognosis across certain cancer types. Nevertheless, its role in gastric cancer (GC) remain poorly characterized.
methodsWe conducted a comprehensive investigation of GRB14 in GC, integrating bioinformatics analysis with experimental validation. The prognostic significance and functional profile of GRB14 was evaluated through survival analysis and GSEA. Additionally, we analyzed the variations in immune cell infiltration and responses to immunotherapy between groups with low and high expression levels of GRB14. To confirm GRB14 expression in GC tissues, we utilized RT-qPCR, western blot and immunohistochemistry (IHC) analysis. Subsequently, functional experiments were then employed to evaluate the functional role of GRB14 in GC cells.
resultsAnalysis of the TCGA_stomach adenocarcinoma (TCGA_STAD) cohort revealed notable GRB14 upregulation in GC tissues, which was subsequently validated through RT-qPCR, western blot and IHC analyses. Elevated GRB14 expression were found to correlate with poor clinical outcomes. GSEA results showed that the vitamin digestion and absorption, and retinol metabolism pathways were obviously inactivated in the high GRB14 expression group. Moreover, this group exhibited notably lower immune score, stromal score, ESTIMATE score, but higher tumor purity compared to the low GRB14 expression group. Meanwhile, patients in the high GRB14 expression group exhibited significant M2 macrophage infiltration and elevated TIDE scores, suggesting that high GRB14 expression may be linked to an immunosuppressive tumor microenvironment. Functional studies demonstrated that GRB14 deficiency remarkably reduced GC cell proliferation, migration and invasion, but induced cell apoptosis.
conclusionThis evidence highlights that GRB14 may serve as a potential candidate for both prognostic evaluation and therapeutic intervention in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.